|
The Cochrane Collaboration
Cochrane Reviews |
| Explore | New + Updated | Other languages |
|
 |
Hormones for suspected impaired fetal growthSay L, Gülmezoglu AM, Hofmeyr GJ
Bookmark this:
     more ...
SummaryHormones for suspected impaired fetal growthNo evidence to show whether the unborn baby's growth improves when pregnant women take extra oestrogen. Babies in the womb growing more slowly than expected (impaired fetal growth) may be receiving too few nutrients from their mother's blood. Hormones are chemicals produced by glands in the body for growth, metabolism (how the body uses food) and reproduction. Oestrogen (the female hormone) is thought to increase blood flow from pregnant women to their babies, thus potentially providing more nutrients. The review of trials has found no evidence to show whether the baby's growth improves when pregnant women take extra oestrogen. There is no evidence from trials on the effects of oestrogen supplementation on women and their babies.
This is a Cochrane review abstract and plain language summary, prepared and maintained by The Cochrane Collaboration, currently published in The Cochrane Database of Systematic Reviews 2010 Issue 1, Copyright © 2010 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
This version first published online:
April 25. 1995 AbstractBackgroundIt has been suggested that oestrogens may improve fetal growth due to an increase in nutritional supply to the fetus from greater uterine blood flow. ObjectivesThe objective of this review was to assess the effects of hormone administration for suspected impaired fetal growth and perinatal outcome. Search strategyWe searched the Cochrane Pregnancy and Childbirth Group's Trials Register (June 2009). Selection criteriaAcceptably controlled trials of hormone administration for suspected impaired fetal growth which report fetal, perinatal or maternal outcomes. Data collection and analysisEligibility and trial quality were assessed. Main resultsNo studies were included since none of the potentially relevant trials reported clinical outcomes. Authors' conclusionsThere is not enough evidence to evaluate the clinical use of hormone administration for suspected impaired fetal growth. |